<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727126</url>
  </required_header>
  <id_info>
    <org_study_id>GEMBOT</org_study_id>
    <nct_id>NCT03727126</nct_id>
  </id_info>
  <brief_title>Robotic Versus Thoracolaparoscopic Esophagectomy for Esophageal Cancer</brief_title>
  <official_title>Robotic Versus Thoracolaparoscopic Esophagectomy for Carcinoma Esophagus: a Prospective Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GEM Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GEM Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal cancer is a debilitating condition. The treatment involved is complex requiring a
      combination of chemotherapy and surgery in most cases. Complete removal of the tumor and the
      adjacent lymph nodes is of utmost importance in improving the survival. Lymph node yield
      following surgery helps in proper staging of the disease and is an important prognosticating
      variable. It is hypothesized that the lymph node yield following robotic esophagectomy is
      higher than that following thoracolaparoscopic esophagectomy. The study aims to compare the
      short term oncological outcomes following robotic esophagectomy and thoracolaparoscopic
      esophagectomy for carcinoma esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymph node yield</measure>
    <time_frame>7 days after Index Surgery</time_frame>
    <description>Total number of lymph nodes harvested</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical margin status</measure>
    <time_frame>7 days after Index Surgery</time_frame>
    <description>The proximal, distal and circumferential surgical margins will be assessed by pathological evaluation for the presence of tumor and will be assigned an &quot;R&quot; category as defined by the College of American Pathologists. R0 would indicate no evidence of residual tumor. Presence of microscopic tumor at margins would be designated as R1 whereas the presence of macroscopically visible tumor at margins would be designated as R2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Up to 90 days after surgery</time_frame>
    <description>Intraoperative and post operative adverse events assessed by Clavien Dindo classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>During index admission or within 30 days after surgery</time_frame>
    <description>Duration of stay in ICU following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>During index admission or re admission within 30 days</time_frame>
    <description>Length of stay in hospital following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>During index admission or within 90 days following surgery</time_frame>
    <description>Death following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of surgery</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Time taken to complete the surgical procedure recorded in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>During surgery and up to 24 hours after index surgery</time_frame>
    <description>Amount of blood lost during and within 24 hours of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Need for conversion of the procedure to open or other alternate technique</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Robotic esophagectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracolaparoscopic esophagectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic esophagectomy</intervention_name>
    <description>Removal of the esophagus and its draining lymph nodes using robotic surgical instruments</description>
    <arm_group_label>Robotic esophagectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracolaparoscopic esophagectomy</intervention_name>
    <description>Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques</description>
    <arm_group_label>Thoracolaparoscopic esophagectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable esophageal carcinoma, either squamous cell carcinoma or adenocarcinoma in
             the middle or lower part the esophagus

        Exclusion Criteria:

          -  American Society of Anesthesiologists (ASA) class 4 and above

          -  Esophagectomy for other non-malignant conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chinnusamy Palanivelu, MS, MCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>GEM Hospital &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shankar Balasubramanian, MS, MRCS</last_name>
    <role>Study Director</role>
    <affiliation>GEM Hospital &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Sabnis, MS, DNB</last_name>
    <role>Study Director</role>
    <affiliation>GEM Hospital &amp; Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shankar Balasubramanian</last_name>
    <phone>+919910766534</phone>
    <email>shanxar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GEM Hospital &amp; Research Center</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhushan Chittawadagi, MS, DNB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GEM Hospital &amp; Research Center</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641045</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shankar Balasubramanian</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagectomy</keyword>
  <keyword>Robotic esophagectomy</keyword>
  <keyword>Laparoscopic esophagectomy</keyword>
  <keyword>Minimally invasive esophagectomy</keyword>
  <keyword>Ivor Lewis esophagectomy</keyword>
  <keyword>McKeown's esophagectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

